MannKind Corporation (NASDAQ: MNKD) announced completion of patient randomization in its Phase 1b INFLO-1 clinical trial and enrollment of the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE